Sanofi (SNY) and Regeneron Pharmaceuticals‘ (REGN) asthma drug Dupixent succeeded in a final-phase study of patients with “smoker’s lung,” leading SNY stock and REGN stock to rocket Thursday.
In the Phase 3 study, Dupixent led to a 30% reduction in exacerbations associated with COPD, or chronic obstructive pulmonary disease. Exacerbations are episodes of worsening symptoms in the progressive, and potentially fatal, lung disease. The condition is common in former smokers, Naimish Patel said in an interview. Patel heads up Sanofi’s immunology and inflammation drug development.
The results could carve out a new market for Dupixent, an already highly successful treatment for asthma, eczema and a condition that causes nasal polyps.
In premarket trading on today’s stock market, REGN stock surged 8.1% near 812. SNY stock rose 6.9% near 52.20.
More to follow.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Top 1% Biotech 89bio Scores 25% Gain As Battle In Liver Disease Heats Up
The Cream Of The Crop: 5 Biotech Stocks That Outrank 92% Of All Stocks
Watch IBD’s Investing Strategies Show For Actionable Market Insights
Profit From Short-Term Trends With SwingTrader
Options Trading: How To Start Using Options, How To Manage Risk
The post Regeneron, Sanofi Soar On Blow-Out Results In ‘Smoker’s Lung’ appeared first on Investor’s Business Daily.